Voloridge Investment Management
ALLO icon

Voloridge Investment Management’s Allogene Therapeutics ALLO Stock Holding History

Voloridge Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-145,841
Closed -$468K – 1133
2023
Q4 		$468K Sell
145,841
-254,704
-64% -$722K ﹤0.01% 1039
2023
Q3 		$1.27M Sell
400,545
-109,509
-21% -$480K 0.01% 1044
2023
Q2 		$2.53M Sell
510,054
-471,614
-48% -$2.55M 0.01% 915
2023
Q1 		$4.85M Sell
981,668
-62,663
-6% -$402K 0.02% 677
2022
Q4 		$6.57M Buy
1,044,331
+255,058
+32% +$2.36M 0.04% 559
2022
Q3 		$8.52M Sell
789,273
-54,588
-6% -$742K 0.05% 491
2022
Q2 		$9.62M Buy
843,861
+50,366
+6% +$447K 0.05% 452
2022
Q1 		$7.23M Buy
793,495
+512,109
+182% +$5.33M 0.04% 511
2021
Q4 		$4.2M Buy
+281,386
New +$4.96M 0.02% 779
2021
Q1 		– Sell
-51,091
Closed -$1.29M – 1357
2020
Q4 		$1.29M Sell
51,091
-65,254
-56% -$2.13M 0.01% 889
2020
Q3 		$4.39M Sell
116,345
-81,876
-41% -$3.09M 0.04% 479
2020
Q2 		$8.49M Buy
+198,221
New +$7.17M 0.1% 233

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Voloridge Investment Management's ALLO Position: Q1 2024 in Review

Voloridge Investment Management sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 145,841 shares — an estimated $468K sold.

Voloridge Investment Management first reported a position in ALLO in Q2 2020 and held it in 12 quarters. The position peaked at $9.62M in Q2 2022. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Voloridge Investment Management reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 145,841 Allogene Therapeutics shares in Q1 2024, an estimated $468K.
  • Voloridge Investment Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 12 quarters.
  • Voloridge Investment Management's Allogene Therapeutics position peaked at $9.62M in Q2 2022.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Voloridge Investment Management's 13F filing for Q1 2024, filed 15 May 2024.